TASER International, Inc. (NASDAQ: TASR), today announced that on August 30, 2010, the United States District Court for the District of Arizona entered judgment in favor of TASER International, Inc. against Stinger Systems, Inc. on Count One of TASER's complaint and further ordered that "Stinger is hereby adjudged to have infringed claims 2 and 40 of United States Patent No. 6,999,295 ('the '295 patent')" and that "Claims 2 and 40 of the '295 patent are hereby adjudged to be valid and enforceable." The patent infringement claim against Stinger's S-200 is based on TASER's patent on the dual mode "shaped pulse" technology found in the TASER(R) X26(TM), X3(TM), Shockwave, and C2(TM) electronic control device products. The Court's ruling found that the "Flyback Quantum Technology" found in the Stinger S-200 literally infringes TASER's '295 Patent. Shares of TASER soared as much as 2% in pre-market trading.
Alimera Sciences, Inc. (NASDAQ: ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien(R) (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA). Iluvien is Alimera's investigational, sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME). FDA Priority Review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard review time from 10 months to six months. With priority review, Alimera could receive a response from the FDA in the fourth quarter regarding its NDA for Iluvien, which was submitted at the end of June 2010. Alimera shares surged as much as 9% in pre-market trading.
Monsanto Company (NYSE: MON) said Tuesday that it expects ongoing EPS for the fiscal year in the range of $2.40 to $2.45 a share, at the low end of its previous $2.40 to $2.60 guidance range. he company continues to expect free cash flow in the range of $400 million to $500 million for the fiscal year. Shares of monsanto slumped as much as 4% in pre-market trading.
Full Disclosure: None.
Alimera Sciences, Inc. (NASDAQ: ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien(R) (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA). Iluvien is Alimera's investigational, sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME). FDA Priority Review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard review time from 10 months to six months. With priority review, Alimera could receive a response from the FDA in the fourth quarter regarding its NDA for Iluvien, which was submitted at the end of June 2010. Alimera shares surged as much as 9% in pre-market trading.
Monsanto Company (NYSE: MON) said Tuesday that it expects ongoing EPS for the fiscal year in the range of $2.40 to $2.45 a share, at the low end of its previous $2.40 to $2.60 guidance range. he company continues to expect free cash flow in the range of $400 million to $500 million for the fiscal year. Shares of monsanto slumped as much as 4% in pre-market trading.
Full Disclosure: None.
